Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies-Reference-Cited by-同舟云学术

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Published:2021-06-29 Issue:9 Volume:138 Page:811-814
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ghione Paola¹^ORCID,Gu Juan J.²,Attwood Kristopher³,Torka Pallawi¹^ORCID,Goel Shipra¹,Sundaram Suchitra¹,Mavis Cory¹⁴,Johnson Michael¹,Thomas Roshneke¹,McWhite Kenneth¹,Darrall Andrea¹,DeMarco Joseph¹,Kostrewa Jessica¹,Mohr Alice¹,Rivas Leah¹,Neiders Mirdza²,Suresh Lakshmanan²,Segal Brahm H.⁴⁵,Griffiths Elizabeth A.⁴⁶^ORCID,Ramsperger Vince²^ORCID,Shen Long²^ORCID,Hernandez-Ilizaliturri Francisco J.¹⁴^ORCID

Affiliation:

1. Lymphoma Section, Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY;

2. KSL Diagnostics, Buffalo, NY;

3. Department of Biostatistics and Bioinformatics

4. Department of Immunology

5. Infectious Disease Section, Department of Internal Medicine, and

6. Leukemia Section, Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Abstract

Following a similar report on multiple myeloma, Ghione and colleagues report the expected observation that patients with non-Hodgkin lymphoma (NHL) receiving anti-B cell therapies have markedly reduced antibody responses to COVID-19 immunization. Although there is no information regarding T-cell immunity, this suggests that while vaccination is certainly still recommended for this population, patients should be strongly encouraged to maintain social distancing precautions and should be revaccinated after an appropriate interval from the end of their antilymphoma therapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/138/9/811/1820404/bloodbld2021012443.pdf

Reference19 articles.

1. Covid-19: risk factors for severe disease and death;Jordan;BMJ.,2020

2. The relationship of COVID-19 severity with cardiovascular disease and Its traditional risk factors: a systematic review and meta-analysis;Matsushita;Glob Heart.,2020

3. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan;Li;J Allergy Clin Immunol.,2020

4. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study;Passamonti;Lancet Haematol.,2020

5. Persistence and evolution of SARS-CoV-2 in an immunocompromised host;Choi;N Engl J Med.,2020

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies;Vaccine;2024-10

2. SARS-CoV-2-Specific T Lymphocytes Analysis in mRNA-Vaccinated Patients with B-Cell Lymphoid Malignancies on Active Treatment;Vaccines;2024-08-26

3. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study;Journal of Infection and Public Health;2024-07

4. Time to optimize vaccination strategies in blood cancer patients;British Journal of Haematology;2024-06-19

5. Management of vaccinations in patients with non‐Hodgkin lymphoma;British Journal of Haematology;2024-03-26